Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 805 of 5804
-
Less oxygen may save more lives after cardiac arrest, study hints
Disease control TerminatedThe Reduction of oxygen after cardiac arrest (EXACT) is a multi-centre, randomised, controlled trial (RCT) to determine whether reducing oxygen administration to target an oxygen saturation of 90-94%, compared to 98-100%, as soon as possible following successful resuscitation fro…
Phase: NA • Sponsor: Monash University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Two-Drug combo aims to outsmart recurrent brain tumors
Disease control OngoingThis randomized phase II trial studies how well cediranib maleate and olaparib work compared to bevacizumab in treating patients with glioblastoma that has come back (recurrent). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes nee…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Two-Drug cocktail shows promise against tough liver cancer
Disease control CompletedThis phase Ib/II trial studies how well sorafenib tosylate and pembrolizumab work in treating patients with liver cancer that has spread to other parts of the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoc…
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug duo takes on kidney cancer in major trial
Disease control CompletedThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic the…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Brain cancer vaccine trial halted: what we know
⭐️ VACCINE ⭐️ TerminatedThe purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
Phase: PHASE1, PHASE2 • Sponsor: VBI Vaccines Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:30 UTC
-
Gene therapy trial aims to slow duchenne muscular dystrophy in boys
Disease control OngoingThis is a controlled, open-label, single-ascending dose study to evaluate the safety and tolerability of SGT-001 in adolescents and children with Duchenne muscular dystrophy (DMD). Participants will receive a single intravenous (IV) infusion of SGT-001 and will be followed for ap…
Phase: PHASE1, PHASE2 • Sponsor: Solid Biosciences Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New psoriasis drug shows promise in major trial
Disease control CompletedThis is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Zap away tremors: new radiation technique offers hope for patients unsuitable for surgery
Disease control OngoingTo determine the efficacy of frameless Virtual Cone Radiosurgical Thalamotomy for medically refractory tremor resulting from either Essential Tremor or Tremor-Dominant Parkinson's Disease with the Fahn-Tolosa-Marin Tremor Rating Scale (FTMTRS) in patients who are not candidates f…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy aims to keep early lung cancer from returning
Disease control CompletedThis is a randomized multicentre open label phase II study of Durvalumab following Stereotactic Body Radiotherapy (SBRT) in patients with T1-2N0M0 NSCLC. Patients will be randomized 1:1 to follow up or receiving Durvalumab every 4th week for 12 months
Phase: PHASE2 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo shows promise in head and neck cancer battle
Disease control CompletedThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamo…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Immune cells injected into brain show promise against deadly cancer
Disease control Recruiting nowThe main objective of this clinical study is to evaluate the safety and tolerability of NK-92/5.28.z and to determine the maximum tolerated dose or maximum feasible dose (MFD). Recommended phase 2 doses both for intraoperative injections only (RP2Diio) and repetitive injections (…
Phase: PHASE1 • Sponsor: Johann Wolfgang Goethe University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Robot suit aims to get paralyzed patients back on their feet
Disease control OngoingBackground and Rationale: Traumatic spinal cord injury (SCI) affects approximately 12,400 individuals annually in the USA, predominantly impacting healthy young adults aged 20-40 years. Complete SCI above the lumbar region results in paraplegia or tetraplegia, severely compromis…
Phase: NA • Sponsor: University of Pecs • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
A smartphone app may help young cancer survivors get fitter — a trial puts it to the test
Disease control CompletedThis randomized clinical phase III trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with cancer. Regular physical activity after receiving treatment for cancer may help to maintain a healthy weight and…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Laser and immunotherapy combo takes on recurrent brain tumors
Disease control OngoingThe purpose of this study is to test the side effects and efficacy of using Laser Interstitial Thermotherapy (LITT) combined with Pembrolizumab. LITT is a minimally invasive surgical technique that uses a laser to heat brain tumors. Pembrolizumab is an investigational (experimen…
Phase: PHASE1, PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo therapy shows promise for tough blood cancers
Disease control CompletedThe purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. (An event is defined as death or transformation to AML in participants with MDS or CMML, whichever occ…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New antibody combo shows promise against Hard-to-Treat colorectal cancer
Disease control CompletedThis randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it started to other places in the body and cannot be remove…
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Shorter combo therapy shows promise for advanced melanoma
Disease control OngoingThis research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma. The drugs involved in this study are: * Pembrolizumab (Keytruda) * Trametinib (Mekinist) * Dabrafenib (Tafinlar)
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for mantle cell lymphoma: transplant combo vs drug alone in major trial
Disease control OngoingThis phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Immunotherapy with rituximab, may induce c…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug cocktail aims to keep relapsed myeloma in check
Disease control OngoingBased on the need to improve outcomes post second autologous stem cell transplant (ASCT) for multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT, the natural next step is to evaluate maintenance/continuation therapy following second ASCT. …
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New blood test could slash unnecessary antibiotics in sick newborns
Diagnosis CompletedLate-onset neonatal sepsis (LOS), occurring in newborn of at least 7 days of life, is frequently observed in Neonatal Intensive Care Units (NICUs) and potentially severe (mortality, neurologic and respiratory impairments). Despite its high prevalence, a reliable diagnostic remai…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jun 26, 2026 13:26 UTC